# 泪腺设备市场

> 泪道设备市场研究报告（按ProAfrica）-（泪道支架、泪点塞、泪道导管、泪囊鼻腔吻合术设备），按材料（硅胶、水凝胶、高分子、金属），按终端用户（医院、眼科诊所、门诊手术中心），按应用（慢性干眼治疗、外科手术、诊断程序）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.01%
- **2024:** $ 3,420.77 Million
- **2025:** $ 3,558.02 Million
- **2035:** $ 5,272.82 Million
- **Key Players:** Abbott (US), Bausch + Lomb (US), Alcon (CH), Carl Zeiss (DE), Hoya Corporation (JP), Santen Pharmaceutical (JP), Ocular Therapeutix (US), EyeGate Pharmaceuticals (US), Icare Finland (FI)

**Report ID:** MRFR/HC/31621-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/lacrimal-device-market-33448

---

## Market Summary

## **Lacrimal Device Market Overview**

**As per MRFR analysis, the Lacrimal Device Market Size was estimated at 3.42 (USD Billion) in 2024. The Lacrimal Device Market Industry is expected to grow from 3.56 (USD Billion) in 2025 to 5.07 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.01% during the forecast period (2025 - 2034).**

### **Key Lacrimal Device Market Trends Highlighted**

The Lacrimal Device Market is experiencing significant growth driven by an increasing prevalence of ocular disorders and a rising aging population. These factors contribute to a higher demand for effective treatments aimed at addressing issues such as dry eye syndrome, which has gained attention recently. Advances in technology and innovative product offerings are also essential drivers, as they provide better outcomes for patients. The expanding awareness about eye health and the availability of a broader range of lacrimal devices further fuel market growth.

There are numerous opportunities to be explored within this market, particularly in terms of product innovation and development.Companies can focus on creating more effective and user-friendly devices that cater to a wider range of patients.

Collaboration with healthcare providers to enhance treatment options and ensure better accessibility will also prove beneficial. The rise of telemedicine and online consultations can facilitate quicker diagnosis and treatment, further promoting the use of lacrimal devices. Recent trends exhibit a shift towards minimally invasive procedures and patient-centric approaches in treatment. This includes the increasing acceptance of outpatient surgical procedures, which are often less daunting for patients.

Moreover, the demand for biodegradable and biocompatible materials in device manufacturing reflects a growing trend towards sustainable practices.Research and development in regenerative medicine are paving the way for innovative solutions, promoting growth within the lacrimal device sector. As the market evolves, aligning product offerings with changing consumer preferences and technological advancements will be crucial for success.

**Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review**

## **Lacrimal Device Market Drivers**

### Rising Prevalence of Ocular Disorders

The Lacrimal Device Market Industry has observed a significant uptick in the prevalence of ocular disorders, which is a major driver for the growth of this market. Conditions such as dry eye syndrome, lacrimal duct obstruction, and other tear film disorders have become more common due to various factors, including lifestyle changes, environmental stressors, and increased screen time.

As the global population ages, the incidence of these ocular issues is expected to rise even further, leading to a higher demand for lacrimal devices that can alleviate these conditions.This increasing need for effective treatment options fuels the innovation and development of new products within the lacrimal device segment. Additionally, advancements in medical technology are enhancing the effectiveness and safety of lacrimal procedures, encouraging healthcare professionals to recommend these devices to their patients.

As awareness about ocular health improves and patients seek solutions for their ocular disorders, the Lacrimal Device Market Industry is poised for sustained growth during the forecast period.This trend highlights the importance of developing comprehensive treatment plans that include lacrimal devices as essential tools in managing and improving eye health.

### Technological Advancements

Innovations and advancements in technology have significantly contributed to the growth of the Lacrimal Device Market Industry. With the introduction of advanced materials, improved design, and minimally invasive procedures, lacrimal devices are becoming more efficient and comfortable for patients. Modern lacrimal devices are designed to offer enhanced durability and lower risk of complications, making them more appealing to both healthcare providers and patients.These technological enhancements allow for better personalization in treatments, thus catering to individual patient needs. As this trend continues, it is expected to drive higher adoption rates and support market expansion.

### Increased Healthcare Expenditure

Global healthcare expenditure is on the rise, with governments and private entities investing more in health services, including ocular care. This increase in spending promotes the adoption of advanced medical devices and technologies, including lacrimal devices. Increased funding supports research and development, leading to more innovative and effective products entering the Lacrimal Device Market Industry. As healthcare systems evolve to improve patient outcomes, the demand for effective treatments for ocular disorders continues to climb, further accelerating market growth.

## **Lacrimal Device Market Segment Insights**

### **Lacrimal Device Market Product Type Insights  **

The Lacrimal Device Market is an integral component of the healthcare industry, with varied product types catering to specific ophthalmic needs. In 2023, the market is valued at 3.16 USD Billion, with expected growth driven by clinical advancements and increasing awareness of ocular health. Among the diverse product types, Lacrimal Stents hold a significant position with a valuation of 0.95 USD Billion in 2023 and are projected to reach 1.35 USD Billion by 2032, showcasing their vital role in treating lacrimal duct obstructions.

Punctal Plugs, valued at 1.05 USD Billion in 2023, emerge as a dominant segment, expected to grow to 1.5 USD Billion by 2032. Their significance arises from their practical utility in managing dry eye syndrome and their minimally invasive nature, appealing to both patients and practitioners. Lacrimal Cannulas, on the other hand, are valued at 0.76 USD Billion in 2023 and are anticipated to rise to 1.1 USD Billion by 2032. Their role in easier administration of treatment across diverse conditions reinforces their necessity in medical practice.

Lastly, Dacryocystorhinostomy Devices, while relatively smaller with a valuation of 0.4 USD Billion in 2023, are projected to increase to 0.55 USD Billion by 2032, marking them as essential in surgical procedures aimed at canalicular obstructions.This segmentation of the Lacrimal Device Market underlines the diverse applications and increasing demand across various product types, shaping future trends and offering substantial opportunities for growth driven by technological advancements and a rising elderly population. The continued evolution of these devices reflects a broader enhancement in patient care and the overall trajectory of industry growth.

**Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review**

### **Lacrimal Device Market Material Insights  **

In 2023, the Lacrimal Device Market was valued at approximately 3.16 (USD Billion) and encompasses various materials crucial for the development of lacrimal devices. The market includes materials such as Silicone, Hydrogel, Polymer, and Metal, each playing a vital role in addressing ocular conditions. Silicone is widely recognized for its flexibility and biocompatibility, making it a preferred choice for many lacrimal devices.

Hydrogel, known for its moisture retention properties, is also significant, providing comfort for the patient over Extended usage.Polymer materials contribute to the market's growth due to their versatility and adaptability in design, while Metal, though less commonly used, offers durability in specific applications. Overall, the Lacrimal Device Market is experiencing growth, driven by the rising prevalence of eye disorders and the demand for innovative treatment options, supported by improvements in technology and material sciences. The expected CAGR of 4.01 from 2024 to 2032 reflects the market's potential for expansion as advancements continue to meet patient needs and preferences.

### **Lacrimal Device Market End User Insights  **** **

The Lacrimal Device Market is projected to reach a valuation of 3.16 USD Billion in 2023, reflecting a steady demand across various end users, including Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers. Hospitals play a critical role in delivering comprehensive eye care and are often equipped with advanced lacrimal devices, making them a dominant player in the market. Meanwhile, Ophthalmology Clinics specialize in ocular treatments and have reported significant growth due to an increasing patient base requiring specialized care.

Ambulatory Surgical Centers also contribute significantly, driven by their capacity to provide outpatient procedures, thus reducing overall healthcare costs and improving patient convenience. The diverse applications of lacrimal devices across these end users contribute to the overall market growth as healthcare providers adapt to evolving patient needs. Moreover, factors such as the rising prevalence of eye-related disorders and growing awareness about eye health are expected to propel market expansion.

However, challenges such as reimbursement issues and high costs of advanced devices may hinder growth.The Lacrimal Device Market data denoting these trends showcases a vibrant and evolving landscape, highlighting the critical importance of strategic positioning within varied healthcare settings.

### **Lacrimal Device Market Application Insights  **

The Lacrimal Device Market is projected to have a significant value of 3.16 billion USD as of 2023, reflecting its growing importance in the healthcare landscape. This market is primarily segmented by application into areas such as Chronic Dry Eye Treatment, Surgical Procedures, and Diagnostic Procedures. Chronic Dry Eye Treatment dominates the market due to the increasing prevalence of dry eye conditions driven by factors like environmental stressors and prolonged screen time. Surgical Procedures are also vital, as advancements in technology have led to enhanced surgical techniques that improve patient outcomes.

Furthermore, Diagnostic Procedures hold significant relevance as early diagnosis and monitoring are crucial in managing lacrimal system disorders effectively. These applications collectively reflect the evolving dynamics of the Lacrimal Device Market, highlighting trends such as an aging population, rising healthcare expenditure, and the growing awareness of eye health issues, contributing to the market's steady growth. Overall, trends in the Lacrimal Device Market statistics suggest robust growth driven by a blend of innovation and increasing healthcare needs globally.

### **Lacrimal Device Market Regional Insights  **

The Lacrimal Device Market is poised for substantial growth across various regions. In 2023, the North American segment dominated, holding a valuation of 1.25 USD Billion, projected to reach 1.79 USD Billion by 2032, showcasing its majority holding in the market. Europe follows as a significant player, starting at 0.9 USD Billion in 2023 and expected to grow to 1.27 USD Billion by 2032. The APAC region, though currently valued at 0.7 USD Billion, is anticipated to expand considerably, with projections of 1.01 USD Billion by 2032, reflecting increasing awareness and healthcare advancements.

South America and MEA present smaller market segments, valued at 0.15 USD Billion and 0.16 USD Billion in 2023, respectively, and expected to grow to 0.22 USD Billion and 0.21 USD Billion by 2032. These regions indicate opportunities for market penetration and investment, particularly as healthcare infrastructure evolves. The overall market growth is driven by rising awareness of lacrimal device applications, technological advancements, and the need for effective treatment options. Understanding the Lacrimal Device Market statistics helps stakeholders navigate a rapidly evolving landscape.

**Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review**

## **Lacrimal Device Market Key Players and Competitive Insights**

The Lacrimal Device Market is an arena characterized by a diverse array of players, reflecting a blend of both established firms and emerging entities that compete in the manufacturing and distribution of devices designed to treat conditions related to lacrimal drainage systems. Competition in this sector is driven by factors such as technological advancements, patient care innovations, and an increasing prevalence of eye-related health issues. The market landscape showcases a commitment to research and development, which is crucial for obtaining regulatory approvals and ensuring the efficacy of lacrimal devices.

Firms often engage in strategic collaborations, mergers, and acquisitions to enhance their product offerings and expand their geographical reach, all while maintaining a focus on patient outcomes and operational efficiency.Glaukos Corporation emerges as a notable competitor within the Lacrimal Device Market, recognized for its innovative approaches and strong emphasis on technology integration in ophthalmic solutions. The company has effectively carved out a niche by developing minimally invasive surgical devices that align with the rising demand for less invasive options in treating lacrimal dysfunction. Its strategic focus on providing a comprehensive suite of products has solidified its market presence.

Glaukos Corporation's strengths lie in its research capabilities and its agility in adapting to the evolving needs of healthcare providers and patients.

By prioritizing clinical efficacy and safety, the company has positioned itself as a leader in pioneering technologies aimed at improving patient experiences and outcomes in eye care.Carl Zeiss AG is another significant player in the Lacrimal Device Market, known for its extensive expertise in optics and imaging solutions. The company's commitment to high-quality precision instruments has translated into robust offerings within the lacrimal device segment. Carl Zeiss AG benefits from a long-standing reputation for excellence in engineering and innovation, leveraging its technological advancements to enhance diagnostic and therapeutic solutions in the ophthalmology market.

Its diverse portfolio includes cutting-edge devices that facilitate the effective treatment of lacrimal system disorders. The company remains committed to extensive research and development efforts, ensuring that it continues to lead the market in terms of technological advancements and maintains strong relationships with healthcare professionals, ultimately translating into superior patient satisfaction in ophthalmic care.

### **Key Companies in the Lacrimal Device Market Include**

- Glaukos Corporation
- Carl Zeiss AG
- EyeGate Pharmaceuticals
- Hoya Corporation
- AbbVie
- Hollister Incorporated
- Johnson and  Johnson
- MediNatura
- TheraTears
- Ocular Therapeutix
- Shire Pharmaceuticals
- Bausch Health
- Alcon
- Novartis
- Santen Pharmaceutical

## Lacrimal Device Market Industry Developments

- **Q2 2024: Eagle Pharmaceuticals Announces FDA Approval of Barhemsys® (amisulpride injection) for the Treatment of Postoperative Nausea and Vomiting in Patients Who Have Failed Prior Antiemetic Therapy** Eagle Pharmaceuticals received FDA approval for Barhemsys®, which includes a novel delivery system for the drug that leverages lacrimal device technology to improve patient outcomes in postoperative care.
- **Q1 2024: Oculogica Announces Strategic Partnership with TearSolutions to Advance Lacrimal Device Innovation** Oculogica and TearSolutions entered a partnership to co-develop next-generation lacrimal devices aimed at improving the diagnosis and treatment of dry eye disease.
- **Q2 2024: LacriSciences Raises $12 Million in Series A Funding to Accelerate Development of Minimally Invasive Lacrimal Stents** LacriSciences secured $12 million in Series A funding to support clinical trials and regulatory submissions for its new minimally invasive lacrimal stent technology.
- **Q3 2024: FDA Grants 510(k) Clearance to MedLac's SmartLacrimal Stent for Chronic Epiphora** MedLac received 510(k) clearance from the FDA for its SmartLacrimal Stent, designed to provide long-term relief for patients suffering from chronic epiphora.
- **Q2 2025: TearRestore Announces Opening of New Manufacturing Facility in Texas to Meet Growing Demand for Lacrimal Devices** TearRestore opened a new manufacturing facility in Texas, expanding its production capacity for lacrimal devices used in the treatment of dry eye and tear duct disorders.
- **Q1 2025: Oculogica Appoints Dr. Maria Chen as Chief Medical Officer to Lead Lacrimal Device Clinical Programs** Oculogica appointed Dr. Maria Chen as Chief Medical Officer to oversee clinical development and regulatory strategy for its lacrimal device portfolio.
- **Q2 2024: TearSolutions Receives CE Mark Approval for LacriPlug, Expanding Access to European Markets** TearSolutions received CE Mark approval for its LacriPlug device, enabling commercialization and distribution across the European Union.
- **Q3 2024: LacriSciences Signs Distribution Agreement with MedTech Europe for Innovative Lacrimal Stent** LacriSciences entered a distribution agreement with MedTech Europe to expand the reach of its innovative lacrimal stent across key European markets.
- **Q4 2024: FDA Approves TearRestore's Next-Generation Punctal Plug for Dry Eye Management** TearRestore received FDA approval for its next-generation punctal plug, designed to provide improved retention and patient comfort for dry eye management.
- **Q1 2025: Oculogica Completes Acquisition of MicroLac Devices to Expand Lacrimal Product Portfolio** Oculogica completed the acquisition of MicroLac Devices, strengthening its position in the lacrimal device market and broadening its product offerings.
- **Q2 2025: TearSolutions Secures $20 Million Series B Funding to Scale Production of Lacrimal Devices** TearSolutions raised $20 million in Series B funding to expand manufacturing and accelerate commercialization of its lacrimal device products.
- **Q3 2025: MedLac Announces Strategic Partnership with VisionCare Group for U.S. Distribution of SmartLacrimal Stent** MedLac formed a strategic partnership with VisionCare Group to distribute its FDA-cleared SmartLacrimal Stent throughout the United States.

## **Lacrimal Device Market Segmentation Insights**

### **Lacrimal Device Market Product Type Outlook**

- Lacrimal Stents
- Punctal Plugs
- Lacrimal Cannulas
- Dacryocystorhinostomy Devices

### **Lacrimal Device Market Material Outlook**

- Silicone
- Hydrogel
- Polymer
- Metal

### **Lacrimal Device Market End User Outlook**

- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers

### **Lacrimal Device Market Application Outlook**

- Chronic Dry Eye Treatment
- Surgical Procedures
- Diagnostic Procedures

### **Lacrimal Device Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- _Middle East and Africa _

## Market Drivers

### 老年人口增长

全球老龄化人口是全球泪道设备市场行业的重要驱动力。随着人们年龄的增长，他们更容易受到可能需要使用泪道设备的眼部疾病的影响。联合国预测，到2030年，60岁及以上的人口将达到14亿，这可能导致对眼部护理解决方案的需求增加。这一人口结构的变化表明，市场可能会经历持续增长，预计到2035年市场价值将达到52.7亿美元，反映出对有效治疗方案的迫切需求。

### 提高意识和教育

人们对眼睛健康及及时治疗泪道系统疾病的重要性日益关注。全球泪道设备市场受益于针对医疗专业人员和患者的教育倡议。旨在向公众普及眼部疾病症状和治疗方案的宣传活动，有助于提高诊断率，从而增加对泪道设备的需求。这种增强的意识可能会导致人们对眼部护理采取更积极的态度，进一步推动市场增长，因为个人寻求有效的解决方案来应对他们的病症。

### 政府支持和资金

政府旨在改善医疗基础设施和眼科资金的举措正在积极影响全球泪道装置市场行业。各个卫生部门正在分配资源，以增强眼科服务的可及性，包括提供泪道装置。例如，支持眼科学研究和开发的资金项目可以导致新型和改进型设备的推出。这种支持对市场扩展至关重要，因为它不仅增加了可用性，还鼓励了行业内的创新。

### 医疗设备的技术进步

医疗技术的创新正在推动全球泪道设备市场的发展。微创手术和先进材料的引入提高了泪道设备的疗效和安全性。例如，生物相容性材料的发展增强了患者的舒适度，并降低了并发症的风险。这些进展不仅吸引了医疗服务提供者，还鼓励患者寻求治疗。因此，市场预计将实现增长，预计在2025年至2035年间的年复合增长率为4.02%，反映出这些创新解决方案的日益普及。

### 市场趋势和增长预测

全球泪道设备市场行业的特点是各种趋势，表明强劲的增长潜力。当前预测显示，市场将在2024年达到34.2亿美元的价值，预计在2025年至2035年间的年均增长率为4.02%。这些数据突显了对研发的日益投资，以及对创新泪道设备的需求不断上升。这些趋势表明市场环境动态，技术进步和日益增长的意识可能在塑造行业未来方面发挥关键作用。

### 眼部疾病的日益普遍

全球泪道设备市场正在增长，原因是干眼症和泪囊炎等眼部疾病的发病率上升。随着人口老龄化，这些疾病的患病率可能会增加，从而导致对有效治疗方案的需求增加。例如，世界卫生组织指出，全球有数百万人患有慢性眼部疾病，迫切需要使用泪道设备。这一趋势表明，市场可能会显著扩张，预计到2024年市场价值将达到34.2亿美元，到2035年可能达到52.7亿美元。

## Future Outlook

全球泪道设备市场预计将在2024年至2034年间以4.01%的年均增长率增长，推动因素包括技术进步、眼部疾病的日益普遍以及老年人口的增加。

**New opportunities:**

- 投资研发创新的泪道设备，以提高患者的舒适度和疗效。

到2035年，市场预计将表现出强劲增长，反映出技术进步和需求增加。

## Segment Insights

### 泪腺设备市场产品类型洞察

泪道设备市场是医疗保健行业的重要组成部分，具有多种产品类型以满足特定的眼科需求。2023年，市场估值为31.6亿美元，预计由于临床进展和对眼部健康意识的提高而推动增长。在多样化的产品类型中，泪道支架占据了重要地位，2023年的估值为9.5亿美元，预计到2032年将达到13.5亿美元，展示了它们在治疗泪道阻塞中的重要作用。

泪道栓，2023年估值为10.5亿美元，成为一个主导细分市场，预计到2032年将增长至15亿美元。它们的重要性源于其在管理干眼症方面的实用性以及其微创特性，吸引了患者和从业者。泪管导管在2023年的估值为7.6亿美元，预计到2032年将上升至11亿美元。它们在不同病症的治疗中更易于施用的作用强化了其在医疗实践中的必要性。

最后，泪囊鼻腔吻合术设备在2023年的估值为4亿美元，预计到2032年将增加到5.5亿美元，标志着它们在针对泪道阻塞的外科手术中的重要性。这一泪腺设备市场的细分突显了各种产品类型的多样化应用和日益增长的需求，塑造了未来的趋势，并提供了由技术进步和老年人口增加驱动的可观增长机会。这些设备的持续演变反映了患者护理的更广泛提升以及行业增长的整体轨迹。

来源：初级研究、次级研究、市场研究未来数据库和分析师评审

### 泪腺设备市场材料洞察

在2023年，泪器市场的估值约为31.6亿美元，涵盖了多种对泪器开发至关重要的材料。该市场包括硅胶、水凝胶、高分子和金属等材料，每种材料在解决眼部疾病方面都发挥着重要作用。硅胶因其灵活性和生物相容性而广受认可，成为许多泪器的首选。

水凝胶以其保湿特性而闻名，同时在长期使用中为患者提供舒适感。聚合物材料因其设计的多样性和适应性而推动市场增长，而金属虽然使用较少，但在特定应用中提供耐用性。总体而言，泪道设备市场正在增长，受到眼部疾病发病率上升和对创新治疗方案需求的推动，同时技术和材料科学的进步也在支持这一增长。预计2024年至2032年间的年均增长率为4.01，反映出市场在持续满足患者需求和偏好的过程中扩展的潜力。

### 泪腺设备市场终端用户洞察

泪道设备市场预计在2023年达到31.6亿美元的估值，反映出各类终端用户（包括医院、眼科诊所和门诊手术中心）之间的稳定需求。医院在提供全面眼科护理方面发挥着关键作用，通常配备先进的泪道设备，使其成为市场的主导参与者。同时，眼科诊所专注于眼部治疗，由于需要专业护理的患者基础不断增加，报告了显著的增长。

门诊手术中心也作出了重要贡献，因其能够提供门诊手术，从而降低整体医疗成本并提高患者便利性。这些最终用户对泪道设备的多样化应用促进了整体市场增长，因为医疗服务提供者适应不断变化的患者需求。此外，眼部相关疾病的发病率上升以及对眼健康的日益关注等因素预计将推动市场扩张。

然而，报销问题和先进设备的高成本等挑战可能会阻碍增长。泪道设备市场数据表明这些趋势，展示了一个充满活力和不断发展的格局，突显了在不同医疗环境中战略定位的关键重要性。

### 泪腺设备市场应用洞察

泪器市场预计到2023年将达到31.6亿美元，反映出其在医疗保健领域日益重要的地位。该市场主要按应用领域细分，包括慢性干眼治疗、外科手术和诊断程序。由于环境压力和长时间使用屏幕等因素导致干眼症状的日益普遍，慢性干眼治疗在市场中占据主导地位。外科手术同样至关重要，因为技术的进步使外科技术得到了改善，从而提高了患者的治疗效果。

此外，诊断程序具有重要意义，因为早期诊断和监测在有效管理泪道系统疾病中至关重要。这些应用共同反映了泪道设备市场不断发展的动态，突显出老龄化人口、医疗支出增加以及对眼健康问题日益关注等趋势，促进了市场的稳定增长。总体而言，泪道设备市场统计数据中的趋势表明，市场在创新与全球日益增长的医疗需求的推动下，呈现出强劲的增长。

## Regional Market Share Analysis

泪道设备市场在各个地区都有显著增长的潜力。2023年，北美市场占主导地位，估值为12.5亿美元，预计到2032年将达到17.9亿美元，显示出其在市场中的主要份额。欧洲紧随其后，作为一个重要参与者，2023年起始估值为9亿美元，预计到2032年将增长至12.7亿美元。亚太地区虽然目前估值为7亿美元，但预计将大幅扩展，预计到2032年将达到10.1亿美元，反映出人们对泪道设备的认识和医疗保健的进步在不断增加。

南美和中东及非洲市场则较小，2023年估值分别为1.5亿美元和1.6亿美元，预计到2032年将增长至2.2亿美元和2.1亿美元。这些地区表明了市场渗透和投资的机会，特别是在医疗基础设施不断发展的背景下。整体市场增长受到对泪道设备应用的认识提升、技术进步以及对有效治疗方案需求的推动。了解泪道设备市场的统计数据有助于利益相关者在快速变化的环境中导航。

**来源：初步研究，二次研究，_市场研究未来_数据库和分析师评审**

## Competitive Benchmarking

泪器市场是一个由多样化参与者构成的领域，反映了既有成熟企业又有新兴实体在制造和分销旨在治疗泪道系统相关疾病的设备方面的竞争。该行业的竞争受到技术进步、患者护理创新以及眼部健康问题日益普遍等因素的驱动。市场格局展示了对研究和开发的承诺，这对于获得监管批准和确保泪器设备的有效性至关重要。

企业通常通过战略合作、合并和收购来增强其产品供应并扩大地理覆盖范围，同时保持对患者结果和运营效率的关注。Glaukos Corporation作为泪器市场中的一个显著竞争者，以其创新的方法和对眼科解决方案中技术整合的强烈重视而闻名。该公司通过开发与日益增长的对非侵入性治疗泪道功能障碍的需求相一致的微创手术设备，成功地开辟了一个细分市场。其在提供全面产品组合方面的战略重点巩固了其市场地位。

Glaukos Corporation的优势在于其研究能力以及适应医疗服务提供者和患者不断变化需求的灵活性。

通过优先考虑临床有效性和安全性，该公司已将自己定位为在改善患者体验和眼科护理结果方面的领先者。Carl Zeiss AG是泪器市场中的另一个重要参与者，以其在光学和成像解决方案方面的广泛专业知识而闻名。该公司对高质量精密仪器的承诺已转化为泪器设备领域的强大产品。Carl Zeiss AG凭借其在工程和创新方面的长期卓越声誉，利用其技术进步来增强眼科市场中的诊断和治疗解决方案。

其多样化的产品组合包括促进有效治疗泪道系统疾病的尖端设备。该公司仍然致力于广泛的研究和开发工作，确保其在技术进步方面继续引领市场，并与医疗专业人员保持良好关系，最终转化为眼科护理中的卓越患者满意度。

## Recent News & Developments

- **2024年第二季度：Eagle Pharmaceuticals宣布Barhemsys®（阿米舒利注射液）获得FDA批准，用于治疗在先前抗呕吐治疗失败的患者的术后恶心和呕吐** Eagle Pharmaceuticals获得了Barhemsys®的FDA批准，该药物采用了一种新型给药系统，利用泪道装置技术改善术后护理中的患者结果。
- **2024年第一季度：Oculogica宣布与TearSolutions建立战略合作伙伴关系，以推进泪道装置创新** Oculogica与TearSolutions达成合作，共同开发下一代泪道装置，旨在改善干眼病的诊断和治疗。
- **2024年第二季度：LacriSciences获得1200万美元A轮融资，以加速微创泪道支架的开发** LacriSciences获得了1200万美元的A轮融资，以支持其新型微创泪道支架技术的临床试验和监管申请。
- **2024年第三季度：FDA授予MedLac的SmartLacrimal Stent用于慢性泪溢的510(k)清关** MedLac获得了FDA的510(k)清关，其SmartLacrimal Stent旨在为患有慢性泪溢的患者提供长期缓解。
- **2025年第二季度：TearRestore宣布在德克萨斯州开设新制造设施，以满足对泪道装置日益增长的需求** TearRestore在德克萨斯州开设了一家新制造设施，扩大了其用于治疗干眼和泪道疾病的泪道装置的生产能力。
- **2025年第一季度：Oculogica任命Dr. Maria Chen为首席医疗官，负责泪道装置临床项目** Oculogica任命Dr. Maria Chen为首席医疗官，负责其泪道装置产品组合的临床开发和监管战略。
- **2024年第二季度：TearSolutions获得LacriPlug的CE标记批准，扩大进入欧洲市场的机会** TearSolutions获得了其LacriPlug装置的CE标记批准，使其能够在欧盟范围内进行商业化和分销。
- **2024年第三季度：LacriSciences与MedTech Europe签署分销协议，以推广创新泪道支架** LacriSciences与MedTech Europe达成分销协议，以扩大其创新泪道支架在主要欧洲市场的覆盖范围。
- **2024年第四季度：FDA批准TearRestore的下一代泪道塞用于干眼管理** TearRestore获得了FDA批准，其下一代泪道塞旨在为干眼管理提供更好的保留和患者舒适度。
- **2025年第一季度：Oculogica完成对MicroLac Devices的收购，以扩展泪道产品组合** Oculogica完成了对MicroLac Devices的收购，增强了其在泪道装置市场的地位，并扩大了其产品供应。
- **2025年第二季度：TearSolutions获得2000万美元B轮融资，以扩大泪道装置的生产** TearSolutions获得了2000万美元的B轮融资，以扩大制造能力并加速其泪道装置产品的商业化。
- **2025年第三季度：MedLac宣布与VisionCare Group建立战略合作伙伴关系，以在美国分销SmartLacrimal Stent** MedLac与VisionCare Group建立了战略合作伙伴关系，以在美国分销其获得FDA批准的SmartLacrimal Stent。

## Report Scope

| 报告属性/指标 | 详细信息 |
| --- | --- |
| 2024年市场规模 |    3.42（十亿美元） |
| 2025年市场规模 |    3.56（十亿美元） |
| 2035年市场规模 | 5.27（十亿美元） |
| 年复合增长率（CAGR） | 4.01%（2025 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2020 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | Glaukos Corporation, Carl Zeiss AG, EyeGate Pharmaceuticals, Hoya Corporation, AbbVie, Hollister Incorporated, Johnson  and  Johnson, MediNatura, TheraTears, Ocular Therapeutix, Shire Pharmaceuticals, Bausch Health, Alcon, Novartis, Santen Pharmaceutical |
| 覆盖的细分市场 | 产品类型、材料、最终用户、应用、区域 |
| 主要市场机会 | 干眼症的流行率上升、老年人口增加、微创技术的进步、眼健康意识的提高、眼科远程医疗的扩展 |
| 主要市场动态 | 眼部疾病的流行率增加、老年人口增长、外科技术的进步、眼健康意识的提高、对微创手术的需求 |
| 覆盖的国家 | 北美、欧洲、亚太地区、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 泪器市场的预计增长是多少？**
A: 泪器市场预计在2025年至2035年的预测期内，总市场价值将增加52.7亿美元。推动这一增长的因素包括需求趋势、技术进步、监管变化和地理扩张。

**Q: 泪腺装置市场的规模是多少？**
A: 泪器市场规模在2024年估计约为34.2亿美元。预计到2035年，该数字将达到52.7亿美元，涵盖所有地区（美洲、欧洲、亚洲、中东和非洲及其他地区），重点关注其细分市场/服务/分销渠道。

**Q: 泪器市场的CAGR是多少？**
A: 泪腺设备市场预计在2025年至2035年间以4.01%的年均增长率增长。

**Q: 到2035年，泪腺装置市场将值多少钱？**
A: 泪器市场预计到2035年底将达到52.7亿美元，反映出使用、技术和全球需求驱动的增长。

**Q: 泪腺装置市场在未来10年将如何表现？**
A: 在接下来的10年中，泪器市场预计将从34.2亿美元转变为52.7亿美元，主要受先进技术的采用、人口趋势、监管批准的推动，但在2025年至2035年期间可能面临一些挑战。

**Q: 2024年哪个地区在泪道设备市场中占据了最大的市场份额？**
A: 在2024年，北美占据了最大的市场份额，价值12.5亿美元。

**Q: 到2035年，欧洲泪道设备市场预计将增长多少？**
A: 到2035年，欧洲泪道设备市场预计将增长至12.7亿美元。

**Q: 2024年泪道支架的市场价值是多少？**
A: 2024年泪道支架的市场价值为9.5亿美元。

**Q: 泪器市场的关键参与者是谁？**
A: 市场的主要参与者包括Glaukos Corporation、Carl Zeiss AG和Johnson and Johnson。

**Q: 到2035年，泪点塞的预计市场规模是多少？**
A: 预计到2035年，泪点塞的市场规模将达到15亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/lacrimal-device-market-33448*